Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PolyPid Ltd
PYPD | US
4.31
USD-0.06
-1.37%
PYPD | US
About PolyPid Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/04/2026
Close
4.31
Open
4.28
High
4.41
Low
4.26
PolyPid Ltd. a clinical-stage pharmaceutical company develops manufactures and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100 which helps in the prevention of sternal (bone) surgical site infections (SSIs) as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing OncoPLEX for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva Israel.
View LessPYPD | US
Risk
46.8
Sharpe
1.52
Luna's Score
43/100
Recommendation
Sell
Luna says (PYPD | US)
What's Working
Strong Sharpe Ratio (> 1.2)
What's not Working
Negative Momentum (Declining Price)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
40.8%1 month
46.8%3 months
44.8%6 months
43.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
14.58
Debt to equity
6.89
Debt to assets
0.56
Ent. to EBITDA
-0.36
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-21.95M
MarketCap
29.32M
MarketCap(USD)
29.32M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-496.62
Short ratio
1.89
Short perc.
0.13
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.42
Range1M
0.66
Range3M
1.11
Volumes: Market Activity
Rel. volume
0.78
Price X volume
186.67K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.36 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 14.58 | 15.55 | Par |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 44.82 | - | Lower Risk |
| Debt to Equity | 6.89 | -1.23 | Expensive |
| Debt to Assets | 0.56 | 0.25 | Expensive |
| Market Cap | 29.32M | - | Emerging |
